Initial Dual Oral CoMbination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary HyperTension
Latest Information Update: 18 Dec 2024
Price :
$35 *
At a glance
- Drugs Macitentan (Primary) ; Riociguat
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms IMPACT-CTEPH
- 16 Dec 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Aug 2025.
- 16 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 18 Jun 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.